MAY 09, 2019 01:30 PM PDT

The NIH Rare Disease Undiagnosed Diseases Network; Lessons Learnt and Challenges Faced in the First Four Years

C.E. CREDITS: CEU | P.A.C.E. CE | Florida CE
Speakers
  • Faculty Investigator, HudsonAlpha Institute for Biotechnology
    Biography
      Liz Worthey, PhD, is a faculty investigator and the director for software development and informatics at the HudsonAlpha Institute for Biotechnology. She is interested in developing new tools for interpreting genomic data. Worthey leads her team in supporting the informatics goals of the institute as well as the clinical mission to provide definitive diagnoses for patients. Worthey received her PhD in genetics from Imperial College London in 2003 and completed her postdoctoral fellowship at the Seattle Biomedical Research Institute at the University of Washington, working on both eukaryotic genomics and other high throughput "omics" projects. In 2008, after working as a project manager for Merck & Co., Worthey joined the Medical College of Wisconsin (MCW) as senior research scientist and became an assistant professor of pediatric genomics in 2010. Worthey became director of genomic informatics for the Human and Molecular Genetics Center at MCW in 2012. She also holds an adjunct assistant professorship in the computer science department at the University of Wisconsin - Milwaukee and adjunct assistant professor positions within the department of pediatrics and department of genetics at the University of Alabama at Birmingham.

      Her lab develops and applies genomic and informatics methods in order to identify and study molecular variation in human disease. A particular focus is on diagnosis in patients with rare or undiagnosed disease. They develop a variety of tools and methods to study the impact of variation and are interested in identifying and studying not only causal variation, but also genetic modifiers of disease initiation, progression, and/or disease outcome.

    Abstract:

    In 2014, the Undiagnosed Diseases Network (UDN), which is funded by the NIH, was established as a network of seven clinical sites, two sequencing cores, and a coordinating center. Later, a central biorepository, a metabolomics core, and a model organisms screening center were added. The aim of the UDN was to provide wider access to cross-disciplinary expertise and to leverage specific advantages of the collaborative network, such as deep subspecialty expertise. The sequencing cores were divided by methodology; the sequencing core at MCW, which subsequently moved to HudsonAlpha made use of WGS, whilst the other core at Baylor College of Medicine (BCM) made use of ES. 

    The hypothesis set out by the WGS site was that application of WGS would lead to an increase in molecular diagnoses of 25%. This talk will explore whether this hypothesis was proven out and will discuss the challenges faced and lessons learned during the first four years of the UDN.

    Learning Objectives: 

    1. To define the meaning of genomic medicine.
    2. To review benefits, challenges, and potential limitations of genomic medicine.
    3. To describe the challenges faced when interpreting genomic data.
    4. To understand how clinical WGS has a number of applied case example within the rare disease space.
     


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    NOV 18, 2019 07:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 26, 2019 09:00 AM PDT
    C.E. CREDITS
    JUN 26, 2019 09:00 AM PDT
    DATE: June 26, 2019TIME: 9:00am PDT, 12:00pm EDT An excessive number of software solutions are available to help manage your clinical, biobank, or biorepository sample inform...
    Loading Comments...
    Show Resources